{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:17:02Z","timestamp":1790288222856,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003151","name":"Fonds qu\u00e9b\u00e9cois de la recherche sur la nature et les technologies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005242","name":"Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024353","name":"Canadian Generic Pharmaceutical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.115006","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:59:48Z","timestamp":1778284788000},"page":"115006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Neutrophil-targeted liposomal inhibition of PAD4-mediated NETosis in systemic lupus erythematosus"],"prefix":"10.1016","volume":"395","author":[{"given":"Nastaran","family":"Rezaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Moawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Stepanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaliroi","family":"Peqini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Q.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Marleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2026.115006_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115006_bb0015","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115006_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/pathophysiology32040061","article-title":"Immunopathogenesis of systemic lupus erythematosus: interplay of innate and adaptive immunity, microbiome dysbiosis, and emerging therapeutic targets","volume":"32","author":"Ahmed","year":"2025","journal-title":"Pathophysiology"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115006_bb0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.33696\/immunology.6.195","article-title":"Advances of immune cells in the pathogenesis and targeted therapy of systemic lupus erythematosus","volume":"6","author":"Fang","year":"2024","journal-title":"J. Cell. Immunol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115006_bb0030","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.17219\/acem\/193892","article-title":"Novel therapies in SLE treatment: a literature review","volume":"34","author":"Mastalerz","year":"2025","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115006_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.980079","article-title":"Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment","volume":"13","author":"Kirou","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115006_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004780","article-title":"Anifrolumab: the new frontier in the treatment of genetic interferonopathies","volume":"10","author":"Fr\u00e9mond","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jconrel.2026.115006_bb0045","article-title":"Cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor-based therapy?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115006_bb0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-target in systemic lupus erythematosus: advancing towards its implementation","volume":"18","author":"Parra S\u00e1nchez","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115006_bb0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/jcm10020243","article-title":"The main challenges in systemic lupus erythematosus: where do we stand?","volume":"10","author":"Piga","year":"2021","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115006_bb0060","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1172\/JCI67390","article-title":"Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus","volume":"123","author":"Knight","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0065","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115006_bb0070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12016-020-08804-7","article-title":"A review of neutrophil extracellular traps (NETs) in disease: potential anti-NETs therapeutics","volume":"61","author":"Mutua","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jconrel.2026.115006_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.104042","article-title":"Recent developments of nanomedicine delivery systems for the treatment of pancreatic cancer","volume":"79","author":"Rezaei","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115006_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229184","article-title":"LOX-1: a potential driver of cardiovascular risk in SLE patients","volume":"15","author":"Sagar","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/ATVBAHA.120.315421","article-title":"Role of LOX-1 (lectin-like oxidized low-density lipoprotein receptor 1) as a cardiovascular risk predictor: mechanistic insight and potential clinical use","volume":"41","author":"Barreto","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jconrel.2026.115006_bb0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2018.03.004","article-title":"Systemic study of solvent-assisted active loading of gambogic acid into liposomes and its formulation optimization for improved delivery","volume":"166","author":"Tang","year":"2018","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0003-2697(80)90269-9","article-title":"Colorimetric determination of phospholipids with ammonium ferrothiocyanate","volume":"104","author":"Stewart","year":"1980","journal-title":"Anal. Biochem."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115006_bb0100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/psc.355","article-title":"Solid phase synthesis of hydrophobic difficult sequence peptides on BDDMA-PS support","volume":"7","author":"Ajikumar","year":"2001","journal-title":"J. Pept. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-024-03058-3","article-title":"Apoptotic body based biomimetic hybrid nanovesicles to attenuate cytokine storms for sepsis treatment","volume":"22","author":"Lan","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115006_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052643","article-title":"Molecular interactions of tannic acid with proteins associated with SARS-CoV-2 infectivity","volume":"23","author":"Haddad","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115006_bb0120","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/pharmaceutics14030543","article-title":"Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application","volume":"14","author":"Lombardo","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115006_bb0125","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3390\/biomedicines10092137","article-title":"Lipid-based drug delivery systems for diseases managements","volume":"10","author":"Gbian","year":"2022","journal-title":"Biomedicines"},{"issue":"14","key":"10.1016\/j.jconrel.2026.115006_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411686","article-title":"From design to study of liposome-driven drug release part 1: impact of temperature and pH on environment","volume":"24","author":"Kozik","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.jconrel.2026.115006_bb0135","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/la304836e","article-title":"Encapsulation of hydrophobic drugs in Pluronic F127 micelles: effects of drug hydrophobicity, solution temperature, and pH","volume":"29","author":"Basak","year":"2013","journal-title":"Langmuir"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/1556-276X-6-482","article-title":"Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1 H-indole-2-carboxylate","volume":"6","author":"Abreu","year":"2011","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2026.115006_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ifset.2022.103155","article-title":"Effect of phospholipids on membrane characteristics and storage stability of liposomes","volume":"81","author":"Song","year":"2022","journal-title":"Innovative Food Sci. Emerg. Technol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17010036","article-title":"Liposomal formulations: a recent update","volume":"17","author":"Agrawal","year":"2024","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115006_bb0155","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jconrel.2012.07.001","article-title":"Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions","volume":"162","author":"Modi","year":"2012","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0005-2736(86)90105-7","article-title":"Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient","volume":"857","author":"Mayer","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115006_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801002","article-title":"Nanocarriers and their loading strategies","volume":"8","author":"Wang","year":"2019","journal-title":"Adv. Healthc. Mater."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115006_bb0170","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.bbamem.2006.05.028","article-title":"Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient","volume":"1758","author":"Fritze","year":"2006","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115006_bb0175","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/pharmaceutics11090465","article-title":"Development and characterization of the solvent-assisted active loading technology (SALT) for liposomal loading of poorly water-soluble compounds","volume":"11","author":"Pauli","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0180","article-title":"Improved scFv anti-LOX-1 binding activity by fusion with LOX-1-binding peptides","volume":"2017","author":"Hu","year":"2017","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/bc300498d","article-title":"From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker","volume":"24","author":"Gray","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.115006_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123942","article-title":"Understanding the in vitro-in vivo Nexus: advanced correlation models predict clinical performance of liposomal doxorubicin","volume":"654","author":"Gan","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115006_bb0195","series-title":"Liposome technology","first-page":"51","article-title":"Encapsulation of Drugs within Liposomes by pH-Gradient Techniques","author":"Fenske","year":"2016"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115006_bb0200","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3109\/03639045.2014.954582","article-title":"Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions","volume":"41","author":"Shibata","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115006_bb0205","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/01.ATV.20.4.1116","article-title":"Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors","volume":"20","author":"Li","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1476-511X-9-120","article-title":"Role of LOX-1 and ROS in oxidized low-density lipoprotein induced epithelial-mesenchymal transition of NRK52E","volume":"9","author":"Wang","year":"2010","journal-title":"Lipids Health Dis."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115006_bb0215","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1021\/acsnano.2c02084","article-title":"Quantification of available ligand density on the surface of targeted liposomal nanomedicines at the single-particle level","volume":"16","author":"Chen","year":"2022","journal-title":"ACS Nano"},{"issue":"23","key":"10.1016\/j.jconrel.2026.115006_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314974","article-title":"The impact of nanobody density on the targeting efficiency of PEGylated liposomes","volume":"23","author":"Mesquita","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115006_bb0225","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2019.05.010","article-title":"Ligand density on nanoparticles: a parameter with critical impact on nanomedicine","volume":"143","author":"Alkilany","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0230","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/la202734f","article-title":"Comparative study of random and oriented antibody immobilization as measured by dual polarization interferometry and surface plasmon resonance spectroscopy","volume":"28","author":"Song","year":"2012","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2026.115006_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00455","article-title":"Real-time characterization of antibody binding to receptors on living immune cells","volume":"8","author":"Bondza","year":"2017","journal-title":"Front. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.115006_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jim.2009.10.002","article-title":"Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity","volume":"352","author":"Heinrich","year":"2010","journal-title":"J. Immunol. Methods"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115006_bb0245","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.4049\/jimmunol.178.11.7467","article-title":"Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab","volume":"178","author":"Lofgren","year":"2007","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115006_bb0250","doi-asserted-by":"crossref","first-page":"504","DOI":"10.52601\/bpr.2021.210042","article-title":"A review for cell-based screening methods in drug discovery","volume":"7","author":"Wei","year":"2021","journal-title":"Biophys. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0255","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7283239","article-title":"In vitro ELISA and cell-based assays confirm the low immunogenicity of VNAR therapeutic constructs in a mouse model of human RA: an encouraging milestone to further clinical drug development","volume":"2020","author":"Ubah","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115006_bb0260","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1166\/jnn.2009.450","article-title":"Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery","volume":"9","author":"Zhai","year":"2009","journal-title":"J. Nanosci. Nanotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115006_bb0265","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00280-013-2153-6","article-title":"Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats","volume":"71","author":"Zhao","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"33","key":"10.1016\/j.jconrel.2026.115006_bb0270","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.4c06286","article-title":"Marginated neutrophils in the lungs effectively compete for nanoparticles targeted to the endothelium, serving as a part of the reticuloendothelial system","volume":"18","author":"Zamora","year":"2024","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115006_bb0275","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1007\/s10439-009-9702-5","article-title":"Selective targeting of nanocarriers to neutrophils and monocytes","volume":"37","author":"Karathanasis","year":"2009","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115006_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1003871","article-title":"Targeted nanoparticles modify neutrophil function in vivo","volume":"13","author":"V\u00f6ls","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115006_bb0285","first-page":"100","volume":"52","year":"2025","journal-title":"J. Rheumatol"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115006_bb0290","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/328078","article-title":"Systemic lupus erythematosus with and without anti-dsDNA antibodies: analysis from a large monocentric cohort","volume":"2015","author":"Fabrizio","year":"2015","journal-title":"Mediat. Inflamm."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115006_bb0295","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1189\/jlb.0312126","article-title":"G-CSF-activated STAT3 enhances production of the chemokine MIP-2 in bone marrow neutrophils","volume":"92","author":"Nguyen-Jackson","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2026.115006_bb0300","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cca.2020.05.034","article-title":"Uric acid and kidney damage in systemic lupus erythematosus","volume":"508","author":"Dos Santos","year":"2020","journal-title":"Clin. Chim. Acta"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:14:50Z","timestamp":1781255690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":60,"alternative-id":["S0168365926004098"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115006","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutrophil-targeted liposomal inhibition of PAD4-mediated NETosis in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115006"}}